Louis began his career in pharmaceuticals R&D with Roche, Glaxo and SmithKline during which period he achieved international recognition in the discovery of NCEs in infectious diseases. He was one of the UK’s first biotechnology entrepreneurs establishing Xenova and Brax both of which achieved successful exits via IPO and trade sale respectively. He was the first recipient of the Ernst & Young Biotechnology Entrepreneur of the Year Award. Since 2000 he has been active in investing and building businesses in the private and public equity markets across the health sector. Venture capital investments have been with Kurma Partners, Sitka Partners, Noble Group and Alderley Park Ventures. He has considerable executive and non-executive Board experience with over 20 quoted and private companies. He has a Ph.D. from Imperial College, London and D.Sc. from the U of Strathclyde.